"Macrocyclic Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclic compounds with a ring size of approximately 1-4 dozen atoms.
| Descriptor ID |
D047028
|
| MeSH Number(s) |
D04.345
|
| Concept/Terms |
Macrocyclic Compounds- Macrocyclic Compounds
- Compounds, Macrocyclic
- Macrocycle Compounds
- Compounds, Macrocycle
|
Below are MeSH descriptors whose meaning is more general than "Macrocyclic Compounds".
Below are MeSH descriptors whose meaning is more specific than "Macrocyclic Compounds".
This graph shows the total number of publications written about "Macrocyclic Compounds" by people in this website by year, and whether "Macrocyclic Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 8 | 9 | 17 |
| 2018 | 5 | 12 | 17 |
| 2019 | 3 | 4 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Macrocyclic Compounds" by people in Profiles.
-
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019 12; 71(6):1106-1115.
-
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019 09; 71(3):473-485.
-
Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. Eur J Pharm Biopharm. 2019 Jul; 140:109-120.
-
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. Semin Liver Dis. 2019 07; 39(3):354-368.
-
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences. Eur J Gastroenterol Hepatol. 2019 04; 31(4):534-539.
-
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat. 2019 06; 26(6):685-696.
-
Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis. Gastroenterology. 2019 05; 156(6):1650-1660.
-
Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J. 2018 11 22; 15(1):180.
-
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018 12; 62:94-103.
-
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Ann Hepatol. 2018 Oct 16; 17(6):959-968.